The Bulletin
The Times


.

Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

  • Written by The Bulletin
  • UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
  • In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks
  • UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies.

Read more: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

hacklink hack forum hacklink film izle hacklink z_libraryjojobetสล็อตสล็อตvipparkjojobetstakeBetpipoPadişahbetjojobetroyalbetPadişahbetjojobetjojobetcasino siteleriPadişahbetDizipalPadişahbetGalabetmostbetTuloskeskusjojobetjojobetcasibomcasibomesim balkancasibom girismarsbahis girişwww.jmctpolytechnic.orgbetparkbetparknakitbahisjojobetjojobetmeritkingankara escort